374 related articles for article (PubMed ID: 34663309)
1. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
[TBL] [Abstract][Full Text] [Related]
2. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Cheng Y; Ma L; Liu Y; Zhu J; Xin Y; Liu X; Wang Y; Zhang T; Yang C; Wang S; Cui H; Zhang L; Dai J; Shao L; Lin J; Ye J; Liu H
Lung Cancer; 2020 Jul; 145():63-70. PubMed ID: 32408134
[TBL] [Abstract][Full Text] [Related]
5. First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.
Wu Y; Du B; Lv C; Ji X; Lan Y; Yao N; Zhu Y; Lai J
Ann Med; 2023; 55(2):2243967. PubMed ID: 37557185
[TBL] [Abstract][Full Text] [Related]
6. LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab.
Wu Y; Du B; Lv C; Ji X; Lai J
Ann Med; 2023; 55(2):2257227. PubMed ID: 37713583
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.
Kuo CY; Tsai MJ; Hung JY; Lee MH; Wu KL; Tsai YC; Chuang CH; Huang CW; Chen CL; Yang CJ; Chong IW
Kaohsiung J Med Sci; 2024 May; 40(5):467-476. PubMed ID: 38523603
[TBL] [Abstract][Full Text] [Related]
9. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
11. The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis.
Chiu TH; Tung PH; Huang CH; Ju JS; Huang AC; Wang CC; Ko HW; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT
Sci Rep; 2022 Mar; 12(1):4398. PubMed ID: 35292755
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
13. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
Wang H; Xing R; Li M; Zhang M; Wei C; Zhang G; Niu Y; Ma Z; Yan X
BMC Cancer; 2023 Mar; 23(1):289. PubMed ID: 36997925
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
[TBL] [Abstract][Full Text] [Related]
17. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H; Kenmotsu H; Kawabata T; Notsu A; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Takahashi T
Cancer Med; 2021 Nov; 10(21):7503-7513. PubMed ID: 34587359
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.
Mi J; Huang Z; Zhang R; Zeng L; Xu Q; Yang H; Lizaso A; Tong F; Dong X; Yang N; Zhang Y
ESMO Open; 2022 Feb; 7(1):100347. PubMed ID: 34953403
[TBL] [Abstract][Full Text] [Related]
19. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
20. EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study.
Gu W; Zhang H; Lu Y; Li M; Yang S; Liang J; Ye Z; Li Z; He M; Shi X; Wang F; You D; Gu W; Feng W
Cancer Res Treat; 2023 Jul; 55(3):841-850. PubMed ID: 36791768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]